Boehringer Ingelheim
German drugmaker developing survodutide, a glucagon and GLP-1 dual agonist licensed from Zealand Pharma, for obesity and MASH.
Privately held, so there is no share price or analyst coverage.
Peptides in this book
- SurvodutideTrials only
Logo source: Boehringer Ingelheim - CC BY-SA 4.0